NCT02977780 - INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | Biotech Hunter

Enrollment

460

Participants

Timeline

Start Date

February 9, 2017

Primary Completion Date

February 1, 2027

Study Completion Date

April 30, 2027

Conditions

Glioblastoma

Interventions

DRUG

Temozolomide

Temzolomide capsules

DRUG

Neratinib

Neratinib tablets

DRUG

QBS10072S

QBS10072S administered intravenously

Trial Locations (12)

10032

ACTIVE_NOT_RECRUITING

Columbia University Medical Center, New York

10065

ACTIVE_NOT_RECRUITING

Memorial Sloan Kettering Cancer Center, New York

15232

ACTIVE_NOT_RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

22908

COMPLETED

University of Virginia Health System, Charlottesville

35294

ACTIVE_NOT_RECRUITING

University of Alabama at Birmingham, Birmingham

44195

ACTIVE_NOT_RECRUITING

Cleveland Clinic, Cleveland

55905

ACTIVE_NOT_RECRUITING

Mayo Clinic, Rochester

77030

COMPLETED

UT MD Anderson Cancer Center, Houston

84112

ACTIVE_NOT_RECRUITING

Huntsman Cancer Institute, Salt Lake City

02114

ACTIVE_NOT_RECRUITING

Massachusetts General Hospital, Boston

02115

RECRUITING

Dana Farber Cancer Institute, Boston

02903

ACTIVE_NOT_RECRUITING

Lifespan / Rhode Island Hospital, Providence